Výsledky vyhledávání - "Matthias Stölzel"

Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study

Autor: Scott MacDiarmid, Matthias Stölzel, William Gibson, Emad Siddiqui, Marcus J. Drake, Nurul Choudhury, Moses Huang

Publikováno v: European Urology Focus. 3:629-638

The BESIDE study demonstrated that combination therapy (mirabegron and solifenacin 5mg) improved overactive bladder symptoms versus solifenacin 5mg or 10mg, and was well tolerated.To ensure efficacy and safety is maintained in older patients (65 yr),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb71704314963adef5de70a7f97d14d0
https://doi.org/10.1016/j.euf.2017.08.008

Zobrazit plný text záznamu

An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects

Autor: Marcel van Gelderen, John Meijer, Cees Korstanje, Christiane Collins, Matthias Stölzel, Virginie Kerbusch

Publikováno v: The Journal of Clinical Pharmacology. 57:1534-1544

To explore the role of β1-adrenoceptors (ARs) in the heart rate response to the selective β3-adrenoceptor agonist mirabegron, 12 young male volunteers received single oral doses of the nonselective β1/2-AR antagonist propranolol (160 mg), the sele

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7db4e743cbfa2e9d8bd9538ec4e51e2b
https://doi.org/10.1002/jcph.952

Zobrazit plný text záznamu

Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy

Autor: Marcus J. Drake, Jameel Nazir, Tahir Saleem, Moses Huang, Zalmai Hakimi, Aino Fianu-Jonasson, Salman Al-Shukri, Philippe Grise, Matthias Stölzel, Jack Barkin, Scott MacDiarmid, Sender Herschorn, Claire Hemsted, Emad Siddiqui, Beside Investigators

Publikováno v: Journal of Urology. 196:809-818

Purpose: We investigated improvements in overactive bladder and patient reported outcomes in patients with overactive bladder and refractory incontinence treated with mirabegron 50 mg plus solifenacin 5 mg vs solifenacin 5 or 10 mg.Materials and Meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7236bb8503d94865a34c6b5a484d4db
https://doi.org/10.1016/j.juro.2016.03.174

Zobrazit plný text záznamu

Daily mortality and particulate matter in different size classes in Erfurt, Germany

Autor: Wolfgang G. Kreyling, Josef Cyrys, H-Erich Wichmann, Matthias Stölzel, Gabriele Wölke, Mike Pitz, Annette Peters, Susanne Breitner, Joachim Heinrich

The link between elevated concentrations of ambient particulate matter (PM) and increased mortality has been investigated in numerous studies. Here we analyzed the role of different particle size fractions with respect to total and cardio-respiratory

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbdac42b49501ee94b91b859c52989fe
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/39105

Zobrazit plný text záznamu

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the beta(3) Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Autor: Philip Van Kerrebroeck, Matthias Stölzel, Jeffrey Frankel, Angelo Gousse, David Castro-Diaz, Montserrat Espuña-Pons, Sender Herschorn, Adrie Gunther, Jack Barkin, Nancy Martin

Publikováno v: Urology, 82(2), 313-320. Elsevier Inc.

OBJECTIVE To assess the efficacy and tolerability of mirabegron 25 mg and 50 mg once-daily vs placebo in patients with overactive bladder (OAB). MATERIALS AND METHODS Patients >= 18 years with OAB symptoms were recruited to a 2-week, single-blind, pl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92c023f4f5ea855cb6a0ea26582b92fc
https://doi.org/10.1016/j.urology.2013.02.077

Zobrazit plný text záznamu

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Autor: Christopher R. Chapple, Stavros Athanasiou, Marcus J. Drake, Scott MacDiarmid, Sender Herschorn, Matthias Stölzel, David Mitcheson, Emad Siddiqui, Moses Huang, Ahmet Adil Esen, Claire Herholdt, Javier Cambronero, Tahir Saleem

Publikováno v: Drake, M, Chapple, C, Esen, A, Athanasiou, S, Cambronero, J, Mitcheson, D, Herschorn, S, Saleem, T, Huang, M, Siddiqi, E, Stölzel, M, Herholdt, C & MacDiarmid, S 2016, ' Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy : A Randomised, Double-blind, Multicentre, Phase 3b Study (BESIDE) ', European Urology, vol. 70, no. 1, pp. 136-145 . https://doi.org/10.1016/j.eururo.2016.02.030

BackgroundIncontinence has a greater detrimental effect on quality of life than other symptoms of overactive bladder (OAB) and is often difficult to treat with antimuscarinic monotherapy.ObjectiveTo evaluate the efficacy and the safety and tolerabili

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b1a312a5c9ba87bc3cf95cb6637de1
https://avesis.deu.edu.tr/publication/details/0c9842b4-968c-4749-a499-835ddc2711a4/oai

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání